Identifying driver genes in cancer is a difficult task because of the heterogeneity of cancer as well as the complex interactions among genes. As sequencing data become more readily available, there is a growing need for detecting cancer driver genes based on statistical and mathematical modeling methods. Currently, plenty of driver gene identification algorithms have been published, but they fail to achieve consistent results. In order to obtain gene sets with high confidence, we present DriverDetector, an R package providing a convenient workflow for cancer driver genes detection and downstream analysis. We develop the background mutation rate calculating module based on the distance between genes in covariate space and binomial test, followed by the driver gene selection module which integrates 11 methods, including two already recognized approaches, a de novo method, and five variants of Fisher's method which are applied to driver gene identification for the first time. Through verification on 12 TCGA datasets, each method is able to identify a set of confirmed driver genes while the number of resulting genes vary significantly across different methods. For robust driver genes detection, a voting strategy based on 10 of the statistical methods is further applied. Results show that the collective prediction based on the voting strategy demonstrates superiority in achieving the consistency of prediction while ensuring a reasonable number of predicted genes and confirmed drivers. By comparing the results of each cancer dataset, we also find that sample size has a huge impact on the number of predicted genes. For downstream analysis, DriverDetector automatically generates plenty of plots and tables to elaborate the results. We propose DriverDetector as a user-friendly tool promoting early diagnosis of cancer and the development of targeted drugs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733820 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e33582 | DOI Listing |
J Transl Med
January 2025
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Background: Tumor microenvironment (TME), particularly immune cell infiltration, programmed cell death (PCD) and stress, has increasingly become a focal point in colorectal cancer (CRC) treatment. Uncovering the intricate crosstalk between these factors can enhance our understanding of CRC, guide therapeutic strategies, and improve patient prognosis.
Methods: We constructed an immune-related cell death and stress (ICDS) prognostic model utilizing machine learning methodologies.
Invest New Drugs
January 2025
UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
Background: Since MYC is one of the most frequently altered driver genes involved in cancer formation, it is a potential target for new anti-cancer therapies. Historically, however, MYC has proved difficult to target due to the absence of a suitable crevice for binding potential low molecular weight drugs.
Objective: The aim of this study was to evaluate a novel molecular glue, dubbed GT19630, which degrades both MYC and GSPT1, for the treatment of breast cancer.
J Hazard Mater
January 2025
Engineering Research Center of Groundwater Pollution Control and Remediation (Ministry of Education), College of Water Sciences, Beijing Normal University, No 19, Xinjiekouwai Street, Beijing 100875, China. Electronic address:
Electronic mediators are an effective means of enhancing the efficiency of microbial electrochemical electron transfer; however, there are still gaps in understanding the strengthening mechanisms and the efficiency of removing antibiotic resistance genes (ARGs) and antibiotic-resistant bacteria (ARB). This study systematically elucidates the effects of various electron mediators on bioelectrochemical processes, electron transfer efficiency, and the underlying mechanisms that inhibit ARG propagation within sediment microbial fuel cell systems (SMFCs). The results indicate that the addition of electron mediators significantly increased the output voltage (33.
View Article and Find Full Text PDFGenes Chromosomes Cancer
January 2025
Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Infantile myofibromatosis (IM) comprises a wide clinical spectrum, ranging from solitary or multicentric lesions to generalized life-threatening forms. IM is mostly linked to germline or somatic heterozygous mutations in the PDGFRβ tyrosine kinase, encoded by the PDGFRB gene. Treatments for IM range from wait and see approach to systemic chemotherapy, according to the clinical context.
View Article and Find Full Text PDFGenes Chromosomes Cancer
January 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, presenting with heterogeneous clinical and molecular subtypes. While gene fusions are predominantly associated with alveolar RMS, spindle cell RMS, especially congenital and intraosseous variants, are also linked to specific gene fusions. Furthermore, recently, FGFR1 kinase-driven RMSs were published.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!